This post was originally published on The Economic Times
Eyestem Research, a Bangalore-based cell therapy company, announced significant vision improvement in phase 1 trials of its investigational drug product, Eyecyte-RPE, in patients with geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). With all patient injections completed across three cohorts without any serious adverse events (SAE), the first six patients had an average improvement of 14.9 letters in early treatment diabetic retinopathy study (ETDRS) standard vision tests within four to six months post-transplantation. Notably, retinal imaging scans revealed early signs of disease reversal in a handful of patients, indicating a remarkable advancement in cell therapy in ophthalmology.
Jogin Desai, Founder and CEO, Eyestem, said in a statement, “The substantial vision improvement, sustained over a four–six month period in all six patients combined with an excellent safety profile has been very encouraging and has the potential to reshape the landscape of GA treatment globally. It is especially rewarding to see the improvement in the quality of life in these patients. We look forward to exploring
— Read the rest of this post, which was originally published on The Economic Times.
